I Peace, Inc

13 articles about I Peace, Inc

• I Peace, Inc. honored in BioSpectrum Asia Excellence Award 2022 with “Special Recognition in Cell Therapy”

  12/21/2022

  I Peace, Inc. is a Palo Alto-based biotech company focusing on Nobel Prize-winning technology of induced pluripotent stem cells (iPSCs) and has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-sized closed cassette.

• I Peace partners with the California Institute for Regenerative Medicine [CIRM]

  11/1/2022

  PRNewswire -- I Peace, Inc. announced that the company has agreed to join the California Institute for Regenerative Medicine's (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manufacturing Practice (GMP) iPSCs for various research programs funded by CIRM. I Peace has been providing

• A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously: To be presented at ISSCR 2022 Annual Meeting

  6/14/2022

  I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based GMP cell manufacturing CDMO and personal iPSC banking provider, announced that the company has succeeded in developing a propriety automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously.

• I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

  5/11/2022

  With this high-throughput method, the company has already succeeded in identifying 1,547 HLA-homozygous potential donors and has already generated iPSCs.

• I Peace triples GMP cell manufacturing by expanding CDMO facility

  3/14/2022

  I Peace, Inc., a Palo Alto-based biotech start-up, announced that the company had tripled its capacity to manufacture GMP grade iPS cells and iPSC-derived differentiated cells by expanding its facility.

• I Peace’s Cell Manufacturing Facility “Peace Engine Kyoto” now registered as U.S. FDA Drug Establishment

  1/28/2022

  The registration recognizes I Peace’s cell manufacturing facility as suitable for drug manufacturing, based on detailed information submitted to the FDA.

• Koji Tanabe, CEO of I Peace, Inc. honored by World Biz Magazine with “Top 100 Innovation CEO” Award

  9/21/2021

  Koji Tanabe, Founder and CEO of I Peace, Inc. (https://www.ipeace.com ), has been selected by the judges of World Biz Magazine’s annual awards to be a recipient of the “Top 100 Innovation CEO – 2021” (https://www.worldbizmagazine.net/ ).

• Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability

  9/7/2021

  I Peace launched its clinical-grade personalized iPSC banking service in 2020 in Japan and has already banked several individuals’ iPSCs.

• I Peace's cell manufacturing facility "Peace Engine Kyoto" receives third-party certification as US cGMP compliant: the facility now meets the standard for both the US and Japanese markets

  5/25/2021

  I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based biotech start-up focusing on Nobel Prize-winning technology "induced pluripotent stem cells (iPSCs)" received a third-party certification as US FDA cGMP compliant for its manufacturing facility “Peace Engine Kyoto,” in Kyoto Japan.

• I Peace, Inc. and Avery Therapeutics announce collaboration to bring iPSC derived cell therapy for heart failure to the clinic

  12/16/2020

  Avery Therapeutics, a Tucson-based company dedicated to advancing tissue-engineered therapeutics to treat diseases and injuries to human muscle, and I Peace, Inc., a Palo Alto-based biotech startup developing, mass-manufacturing, and commercializing Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs)

• I Peace, Inc. Obtains IRB Approval for Production of Clinical and Research-Grade iPSCs for Commercial Use

  12/3/2020

  I Peace, Inc., a Palo Alto-based biotech start-up focusing on Nobel Prize-winning induced pluripotent stem cell (iPSC) technology obtains approval from an independent Institutional Review Board (IRB) for the process of generating iPSCs—including donor recruiting, screening, blood draw, iPSC generation, storage, and distribution—for commercial use.

• The Alliance for Regenerative Medicine Releases List of Presenting Companies at the 2020 Cell & Gene Meeting on the Mesa

  7/29/2020

  The Alliance for Regenerative Medicine, the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today released the initial slate of presenting companies at its upcoming 2020 Cell & Gene Meeting on the Mesa.

• Stem Cells for Everyone: Revolutionizing Regenerative Medicine with Mass Manufacturing of Induced Pluripotent Stem Cells (iPSCs)

  7/15/2020

  I Peace, Inc. (CEO: Koji Tanabe, https://ipeace.com/), a Palo Alto-based biotech startup focusing on Nobel Prize-wining technology of induced pluripotent stem cells (iPSCs) has successfully developed a novel system to mass manufacture clinical-grade iPSCs for cell therapy in a palm-size closed cassette